Patent SG-11201407975T-A (SG)
Title: Alternaria peptides
Inventor: HAFNER RODERICK PETER
IPC: C07K14/37
Filed: 2013-05-30
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/179043 A1 (51) International Patent Classification: C07K14/37 ( 2006.01) A61P 37/08 (2006.01) A61K39/35 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 1209868.7 1 June 2012 (01.06.2012) (74) Agent: WOODS, Geoffrey Corlett; Kemp & Co., 14 South Square, Gray's Inn, London, Greater London WC1R 5JJ (GB). PCT/GB2013/051439 30 May 2013 (30.05.2013) English (71) Applicant: CIRCASSIA LIMITED [GB/GB]; The Ox­ ford Science Park, Oxford, Oxfordshire OX4 4GA (GB). (72) Inventors: HAFNER, Roderick Peter; Circassia Limited, Magdalen Centre, The Oxford Science Park, Oxford, Ox­ fordshire OX4 4GA (GB). LAIDLER, Paul; Circassia Limited, Magdalen Centre, The Oxford Science Park, Ox­ ford, Oxfordshire OX4 4GA (GB). HICKEY, Pascal; Cir­ cassia Limited, Magdalen Centre, The Oxford Science Park, Oxford, Oxfordshire OX4 4GA (GB). LARCHE, Mark; Department of Medicine HSC 4H20 McMaster University, 1200 Main Street, West Hamilton, Ontario L8N 3Z5 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, GB SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) o o\ l> i-H cn i-H o CJ o & (54) Title: ALTERNARIA PEPTIDES (57) Abstract: Pharmaceutical formulations,which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporiumgenus, comprising pharmaceutically acceptable carrier a or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a)a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT(Alt28; SEQ ID NO: 101) or T a cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b)a polypeptide comprising the amino acid sequence of KYRRWRAGVKVAQTAR(Alt34A; SEQ ID NO: 107) or a T cell epi- tope-containing variant sequence derived from said amino acid sequence, or said a salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or T cell a epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d)a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTY - GQ(Altl3A; SEQ ID NO: 83) or T cell a epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e)a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD(Alt01A; SEQ ID NO: 60)or a T cell epi- tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK(Alt06; SEQ ID NO: 72) or T a cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g)a polypeptide comprising the amino acid sequence of DITYVATATLP - NYCR(SEQ ID NO: 111) or T a cell epitope-containing variant sequence derived from said amino acid sequence, or said a salt thereof; and (h)a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET(Altl4;SEQ ID NO: 84) or T a cell epi- tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide up is to 30 amino acids in length.